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Abstract. Background: The RNASEL G1385A variant was
recently found to be implicated in the development of prostate
cancer. Considering the function of RNase L and the
pleiotropic effects of mutations associated with cancer, we
sought to investigate whether the RNASEL G1385A variant is
a risk factor for breast cancer. Patients and Methods: A total of
453 breast cancer patients and 382 age- and sex-matched
controls from Greece and Turkey were analyzed. Genotyping
for the RNASEL G1385A variant was performed using an
Amplification Refractory Mutation System (ARMS). Results:
Statistical evaluation of the RNASEL G1385A genotype
distribution among breast cancer patients and controls revealed
no significant association between the presence of the risk
genotype and the occurrence of breast cancer. Conclusion:
Although an increasing number of studies report an association
between the RNASEL G1385A variant and prostate cancer
risk, this variant does not appear to be implicated in the
development of breast cancer. 
RNASEL (MIM# 180435) encodes for the ubiquitously
expressed ribonuclease L (RNase L) that mediates antiviral
and pro-apoptotic activities of the 2-5A system (1). The
RNASEL Arg462Gln (G1385A) variant, which has three
times less enzymatic activity than the wild-type, was
recently found to be implicated in up to 13% of prostate
cancer cases (2, 3). Furthermore, germ-line RNASEL
mutations segregating with disease within hereditary
prostate cancer (HPC) families and loss of heterozygosity
(LOH) involving the RNASEL locus in tumor tissues has
been observed (4). RNase L has been proposed to suppress
the development of prostate cancer through its ability to
degrade RNA and initiate a cellular stress response that
leads to apoptosis (1). By fluorescence in situ hybridization,
RNASEL was assigned to 1q25 (5). Cytogenetic studies
have shown that one of the most frequently observed
karyotypic changes seen in breast cancer involve the long
arm of chromosome 1. Analysis of polymorphic DNA
markers to search for allelic losses at this chromosome
region suggested that inactivation of a gene(s) located on
1q23-32, which encompasses the RNASEL locus, might
contribute to the genesis of breast cancer (6). Breast cancer
is a polygenic disorder and inherited mutations have been
observed in BRCA1, BRCA2, ATM, p53 and CHEK2 genes
(7). Interestingly, germ-line mutations in CHEK2
(checkpoint kinase 2, a ubiquitously expressed protein
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kinase) were found to be associated with prostate cancer
risk as well (8). Based on the chromosomal localization and
function of RNASEL, and pleiotropic effects of cancer-
associated mutations as exemplified by CHEK2 in both
breast and prostate cancers or BRCA1 in breast and
ovarian cancers, we sought to investigate the hypothesis
that the Arg462Gln variant of this gene is associated with
breast cancer risk.
Patients and Methods
Peripheral blood samples were collected from 152 Greek and
301 Turkish breast cancer patients (invasive breast carcinoma,
mean age: 49.65, standard deviation: 12.95, age range: 20-86).
They were divided into two groups as premenopausal (n= 203;
mean age: 40.29, standard deviation: 7.82, age range: 20-58), and
postmenopausal (n=250; mean age: 57.40, standard deviation:
11.15, age range: 31-86). At the time of blood donation, each
individual completed a standardized questionnaire that included
information about age and menopausal status (Greece); and
age, menopausal status, age at menarche, age at full term
pregnancy, number of full term pregnancies, family history of
breast cancer, smoking history and height and weight (Turkey).
Histopathology of the tumor was obtained through medical
records. The age-matched control group comprised 164 Greek
and 218 Turkish apparently healthy women with no history of
cancer. They were also divided into two groups as
premenopausal (n=180; mean age: 37.91, standard deviation:
8.05, age range: 15-52) and postmenopausal (n=202; mean age:
58.55, standard deviation: 9.77, age range: 30-88). Informed
consent was obtained from all subjects.
DNA was extracted from peripheral blood and the RNASEL
G1385A mutation was detected using the Amplification
Refractory Mutation System (ARMS) (2). Genotyping was
performed and confirmed by two independent researchers. The
association between the G1385A genotype and incidence of
breast cancer was evaluated statistically using binary logistic
regression (SPSS 9.0.0). 
Results and Discussion
The RNASEL Arg462Gln variant was analyzed in 453
female breast cancer patients and 382 age- and sex-
matched controls. The combined Greek and Turkish
population allele frequencies of the A allele was 0.334
and 0.359 for cases and controls, respectively. Although
the A allele frequency was slightly different between the
two populations (cases: 0.385 and controls: 0.442 Greek;
and cases: 0.309 and controls: 0.298 Turkish), the
genotype distributions in the control groups were in
Hardy-Weinberg equilibrium in both populations. Our
study showed that there is no significant association
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Table I. Distribution of RNASEL G1385A genotypes and breast cancer risk in the age-matched controls and breast cancer patients.
Case Control OR (95% CI) OR (95% CI)
Population Genotype
n=453 (%) n=382 (%) Crude Adjusteda,b
Gr + Tr G/G 206 (45.48) 168 (43.98) 1.00 1.00
G/A 191 (42.16) 153 (40.05) 1.02 (0.76- 1.37) 0.95 (0.70- 1.29) 
A/A 56 (12.36) 61 (15.97) 0.75 (0.49- 1.14) 0.72 (0.46- 1.12) 
G/A or A/A 247 (54.52) 214 (56.02) 0.94 (0.72- 1.24) 0.89 (0.66-1.18) 
Gr G/G 60 (39.47) 59 (35.98) 1.00 1.00 
G/A 67 (44.08) 65 (39.63) 1.01 (0.62- 1.66) 0.78 (0.42- 1.46) 
A/A 25 (16.45) 40 (24.39) 0.62 (0.33- 1.14) 0.67 (0.32- 1.42) 
G/A or A/A 92 (60.53) 105 (64.02) 0.86 (0.55- 1.36) 0.74 (0.42- 1.31) 
Tr G/G 146 (48.50) 109 (50.00) 1.00 1.00 
G/A 124 (41.20) 88 (40.37) 1.05 (0.73- 1.52) 0.77 (0.46- 1.28) 
A/A 31 (10.30) 21 ( 9.63) 1.10 (0.60- 2.02) 1.07 (0.48- 2.39) 
G/A or A/A 155 (51.50) 109 (50.00) 1.06 (0.75- 1.50) 0.82 (0.51-1.33) 
Gr: Greek, Tr: Turkish populations. OR: Odds Ratio, CI: Confidence Interval. ORs and 95% CIs were calculated using binary logistic regression.
Adjusted for aage and menopausal status (Gr, Gr+Tr) and bsmoking status, body mass index, age at menarche, age of 1st pregnancy, number of
children, family history of breast cancer (Tr).
between RNASEL G1385A mutation and breast cancer
risk (t-test, p=0.66) (Table I). Stratification of the data
according to age and menopausal status in the Greek
population; age, menopausal status, smoking status, body
mass index, age at menarche, age of first pregnancy,
number of children, family history of breast cancer in the
Turkish population; or age and menopausal status in both
populations combined, did not change the results.
Inclusion of two different Eastern Mediterranean
populations and a fairly large number of cases and
controls makes this study relatively strong. Given the
sample size and allele frequencies, the study has a power
of 90% to confirm an odds ratio as low as OR = 1.6 at a
significance level of · = 0.05.
In conclusion, our study suggests no significant
association between the RNASEL G1385A variant and
breast cancer risk in the Greek and Turkish populations.
These results may need to be further corroborated by other
investigations and in different populations since this is the
first study reporting on the association of the RNASEL
G1385A variant and breast cancer.
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